Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain

Synapse

Volumn 65, Issue 3, 2011, Pages 257-259

  Owen, David R J ^a   Lewis, Andrew J M ^a   Reynolds, Richard ^a   Rupprecht, Rainer ^b,c   Eser, Daniela ^b   Wilkins, Martin R ^a   Bennacef, Idriss ^a   Nutt, David J ^a   Parker, Christine A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Peripheral benzodiazepine receptor (PSR); Translocator Protien (TSPO)

Indexed keywords

CARRIER PROTEIN; EMAPUNIL; PROTEIN 18 KDA; UNCLASSIFIED DRUG;

ARTICLE; BRAIN; DRUG PROTEIN BINDING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL;

EID: 78650656892     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20884     Document Type: Article

References (9)

1. Brot MD, Akwa Y, Purdy RH, Koob GF, Britton KT. 1997. The anxiolytic-like effects of the neurosteroid allopregnanolone: Interactions with GABA(A) receptors. Eur J Pharmacol 325: 1-7.
2. Imaizumi M, Briard E, Zoghbi SS, Gourley JP, Hong J, Musachio JL, Gladding R, Pike VW, Innis RB, Fujita M. 2007. Kinetic evaluation in nonhuman primates of two new PET ligands for peripheral benzodiazepine receptors in brain. Synapse 61: 595-605.
3. Owen DRJ, Howell OW, Tang SP, Wells LA, Bennacef I, Bergstrom M, Gunn RN, Rabiner EA, Wilkins MR, Reynolds R, Matthews PM, Parker CA. 2010. Mixed Affinity Binding in Humans with 18kDa Translocator Protien (TSPO) Ligands. J Nuclear Medicine 30: 1608-1618.
4. Owen DRJ, Gunn RN, Rabiner EA, Bennacef I, Fujita M, Kreisl WC, Innis RB, Pike VW, Reynolds R, Matthews PM, Parker CA. 2010a. Mixed Affinity Binding in Humans with 18 kDa Translocator Protein (TSPO) Ligands. Journal of Nuclear Medicine. In press.
5. Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapere JJ, Lindemann P, Norenberg MD, Nutt D, Weizman A, Zhang MR, Gavish M. 2006. Translocator protein (18kDa): New nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 27: 402-409.
6. Rupprecht R, Holsboer F. 1999. Neuroactive steroids: Mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 22: 410-416.
7. Rupprecht R, Rammes G, Eser D, Baghai TC, Schule C, Nothdurfter C, Troxler T, Gentsch C, Kalkman HO, Chaperon F, Uzunov V, McAllister KH, Bertaina-Anglade V, La Rochelle CD, Tuerck D, Floesser A, Kiese B, Schumacher M, Landgraf R, Holsboer F, Kucher K. 2009. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 325: 490-493.
8. Strohle A, Romeo E, di MF, Pasini A, Hermann B, Gajewsky G, Holsboer F, Rupprecht R. 2003. Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: Preliminary results. Arch Gen Psychiatry 60: 161-168.
9. Strohle A, Romeo E, di MF, Pasini A, Yassouridis A, Holsboer F, Rupprecht R. 2002. GABA(A) receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment. Am J Psychiatry 159: 145-147.